Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $255

Benzinga Newsdesk www.benzinga.com Positive 82.6%

Neg 0% Neu 0% Pos 82.6%

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $225 to $255.